In routine setting, interdisciplinary teams satisfactorily manage extravasations
the ONA take:
In a routine setting, the standardized management of cytotoxic extravasations of antitumoral compounds by an interdisciplinary task force resulted in a satisfactory outcome, a study published in the journal Supportive Care in Cancer has shown.
For the study, researchers sought to assess extravasations of antitumoral compounds and the efficacy of its structured interdisciplinary managements in a routine setting. Researchers longitudinally observed 169 patients who were managed for cytotoxic extravasation according to a prospective approach. Patients underwent surgery if conservative measures failed.
Results showed that conservative management was successful in 91.7% of patients. Researchers found that extravasations of anthracyclines (i.e., doxorubicin), platinum compounds (i.e., cisplatin), vinca alkaloids (i.e., vincristine), and taxanes (i.e., paclitaxel) were associated with erythema, edema, and pain.
The median duration until full resolution of symptoms was 55 days for anthracyclines, 27 days for taxanes and vinca alkaloids, and 14 days for platinum compounds, with statistical significance between the vesicants.
The findings suggest that "the proposed approach is therefore considered as suitable to manage extravasations in cancer chemotherapy in a large number of subjects and to ensure patient adherence to cytotoxic treatment."
In a routine setting, the standardized management of cytotoxic extravasations resulted in a satisfactory outcome.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|